Biotech 2023: it’s time to plan your fundraising journey.
Unlike other industries, biotech companies require multiple funding cycles to fuel meticulously planned clinical trials that take more than a decade to complete. Biotech companies can’t pause development or quickly pivot to a more profitable product during difficult times. The necessity to continue clinical development of their therapeutics is why choosing to delay investor marketing isn’t a viable option.